Skip to main content

Main navigation

  • About
    • Members
    • Our Team
    • Annual Report
    • Rutgers-NPC Health Policy & Communications Fellowship
    • NPC Summer Scholars
    • Contact Us
  • Topics
    • Health Spending
      • IRA & Medicare Drug Price Negotiation
      • 340B Drug Pricing Program
      • Understanding Health Spending
      • Low-Value Care
      • Health Spend Management
    • Value Assessment
      • Value Assessment Frameworks
      • Value Assessment Methods
      • Elements of Value
    • Alternative Payment Models
      • Value-Based Contracts
      • Regulatory Barriers & Challenges
      • Paying for Cures
      • Accountable Care Organizations
      • Bundled Payments
      • Health Care Quality Measures
      • Clinical Pathways
    • Patient-Centered Formulary & Benefit Design
      • High-Deductible Health Plans
      • Value-Based Insurance Design
      • Utilization Management & Step Therapy
      • Formulary Development
      • Patient Cost Sharing
      • Individual Treatment Effects & Personalized Access
    • Evidence for Decision Making
      • Real-World Data
      • Real-World Evidence
      • Good Practices for Evidence
    • Biopharma Innovation
      • Impact on Outcomes & Spending
  • Resources
    • Research
    • Fact Sheets
    • Policy & Evidence Briefs
    • Letters & Comments
    • E.V.I.dently Today Blog
    • Newsletters
    • Events
    • CER Daily Newsfeed®
    • Press Room
      • NPC in the News
      • NPC Press Releases
    • Videos and Graphics
    • Stakeholder Resources
      • For Employers
      • For Patient Organizations
      • Going Below The Surface
  • Get Involved
    • Become a Member
    • Submit a Research Proposal
    • Start a Career
  • Members Only
    • Value of Membership
      • Strategic Plan
      • Research Pipeline
    • Member Resources
      • Weekly Leadership Memo
      • Government Price-Setting & IRA Implementation Member Resources
      • Value Assessment & ICER-Related Member Resources
      • Health Spending & Drug Pricing Member Resources
      • Other Policy-Relevant Member Resources
    • Member Events
      • Leadership Forums
    • Board of Directors
    • Committees & Workgroups
      • Audit & Budget
      • Board-Level Research Committee
      • Executive Committee
      • Strategic Advisory Group
      • Corresponding Officers
      • Research Work Group
      • Employer Work Group
      • Policy & Communications Work Group
    • Logout
National Pharmaceutical Council

Offscreen menu

User account menu

  • Member Resources

The Cost of 340B to States

  • Read more about The Cost of 340B to States

Are Commercial Insurance Premiums Associated With the 340B Drug Pricing Program?

  • Read more about Are Commercial Insurance Premiums Associated With the 340B Drug Pricing Program?

340B Program Growth Is Associated With Billions in Additional Employer and Employee Insurance Premium Expenses

  • Read more about 340B Program Growth Is Associated With Billions in Additional Employer and Employee Insurance Premium Expenses

Study Finds Higher 340B Profit Margins for Facilities Serving Wealthier Communities, With Stronger Bargaining Positions

  • Read more about Study Finds Higher 340B Profit Margins for Facilities Serving Wealthier Communities, With Stronger Bargaining Positions

The Association of 340B Program Drug Margins with Covered Entity Characteristics

  • Read more about The Association of 340B Program Drug Margins with Covered Entity Characteristics

The Cost of 340B to States and State One-Pagers

  • Read more about The Cost of 340B to States and State One-Pagers

Pagination

  • Next page
  • Page 2
Subscribe to 340B Drug Discount Program

Let's stay in touch.

Subscribe to our newsletter.
© 2026 NPC. All rights reserved.

Footer Menu

  • Accessibility
  • Privacy Policy
  • Terms of Use
  • Contact Us

Footer Social Links Menu

  • Twitter image/svg+xml
  • Linkedin
  • Youtube